Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $266.81 USD
Change Today +4.29 / 1.63%
Volume 443.2K
SHPG On Other Exchanges
Symbol
Exchange
SHPG is not on other exchanges.
As of 8:10 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

shire plc-adr (SHPG) Snapshot

Open
$266.83
Previous Close
$262.52
Day High
$267.63
Day Low
$265.10
52 Week High
07/29/15 - $270.63
52 Week Low
10/15/14 - $156.25
Market Cap
53.4B
Average Volume 10 Days
778.9K
EPS TTM
--
Shares Outstanding
200.2M
EX-Date
03/11/15
P/E TM
--
Dividend
$1.15
Dividend Yield
0.26%
Current Stock Chart for SHIRE PLC-ADR (SHPG)

shire plc-adr (SHPG) Details

Shire plc, a biopharmaceutical company, together with its subsidiaries, researches, develops, licenses, manufactures, markets, distributes, and sells pharmaceutical products. It offers various products for the treatment of attention deficit hyperactivity disorder (ADHD), including VYVANSE/ VENVANSE/ ELVANSE/ TYVENSE/ ELVANS E VUXEN/ADUVANZ; INTUNIV, an alpha-2A receptor agonist; EQUASYM, a methylphenidate hydrochloride; and ADDERALL XR, an extended release treatment for ADHD. The company also provides BUCCOLAM for epilepsy treatment; PENTASA and LIALDA/MEZAVANT for ulcerative colitis treatment; and RESOLOR, a 5-HT4 receptor agonist that is used for the treatment of chronic constipation in women. In addition, it offers REPLAGAL for the treatment of Fabry disease; ELAPRASE for the treatment of hunter syndrome; VPRIV for the treatment of type 1 Gaucher disease; and FIRAZYR and CINRYZE C1 esterase inhibitor for the treatment of hereditary angioedema. Further, the company provides FOSRENOL, a phosphate binder for use in end-stage renal disease receiving dialysis; XAGRID that is used for the reduction of elevated platelet counts in at-risk essential thrombocythemia patients; and PLENADREN for the treatment of adrenal insufficiency. Additionally, it licenses its patented antiviral products for human immunodeficiency virus and hepatitis B virus. The company also focuses on the development of resources projects in various therapeutic areas, including rare diseases, neuroscience, ophthalmics, hematology, and gastrointestinal disorders; and early development projects primarily on rare diseases. Shire plc markets its products through wholesalers and pharmacies. The company has research collaboration with ArmaGen Technologies Inc., Santaris Pharma A/S, and Sangamo. Shire plc was founded in 1986 and is based in Dublin, Ireland.

5,016 Employees
Last Reported Date: 02/24/15
Founded in 1986

shire plc-adr (SHPG) Top Compensated Officers

Chief Executive Officer, Managing Director an...
Total Annual Compensation: $3.6M
Compensation as of Fiscal Year 2014.

shire plc-adr (SHPG) Key Developments

Shire plc Resolves to Pay an Interim Dividend for the Six Months Ended June 30, 2015, Payable on October 2, 2015

In respect of the six months ended June 30, 2015 the Board of Shire plc resolved to pay an interim dividend of 4.21 cents per ordinary share compared to 3.83 cents per ordinary share paid a year ago. Dividend payments will be made in Pounds Sterling to holders of Ordinary Shares and in US Dollars to holders of ADS's. A dividend of 2.69 pence per Ordinary Share (an increase of 20% compared to 2014: 2.24 pence) and 12.63 cents per ADS (an increase of 10% compared to 2014: 11.49 cents) will be paid on October 2, 2015 to shareholders on the register as at the close of business on September 4, 2015.

Shire plc Announces Interim Dividend

The board of Shire plc has approved an interim dividend of USD 4.21 per ordinary share, up from USD 3.83 a year earlier.

Shire plc Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Provides Earnings Guidance for the 2015 and 2016; Reports Impairment Charges for the Second Quarter Ended June 30, 2015

Shire plc reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the period, the company reported total revenues of $1,557.6 million against $1,502.1 million for the same period in the last year. Operating income from continuing operations was $132.6 million against $337.9 million for the same period in the last year. Income from continuing operations before income taxes and equity in losses of equity method investees was $119.9 million against $348.8 million for the same period in the last year. Income from continuing operations, net of tax was $164.1 million against $528.3 million a year ago. Net income was $159.6 million against $523.1 million for the same period in the last year. Non GAAP diluted earnings per American Depository share were $2.63 against $2.67 a year ago. US GAAP basis diluted earnings per ADS were $0.81 against $2.66 a year ago. Net cash provided by operating activities was $452.3 million against $834.0 a year ago. Net debt, Non GAAP measure, at June 30, 2015 was $2,253.4 million against $2,118.7, at December 31, 2014. Purchases of non-current investments were $2.4 million against $2.8 million for the same period in the last year. Purchases of PP&E were $20.5 million against $3.8 million for the same period in the last year. Non GAAP EBITDA was $653.9 million against $674.9 million for the same period in the last year. Non-GAAP operating income from continuing operations was $614.0 million against $630.2 million for the same period in the last year. Non GAAP cash generation was $505.3 million against $658.6 million a year ago. Capital expenditure was $20.5 million against $3.8 million a year ago. The company ended the quarter with net debt of $2.25 billion. For the six months, the company reported total revenues of $3,046.0 million against $2,848.9 million for the same period in the last year. Operating income from continuing operations was $607.2 million against $644.8 million for the same period in the last year. Income from continuing operations before income taxes and equity in losses of equity method investees was $591.2 million against $653.1 million for the same period in the last year. Income from continuing operations, net of tax was $577.0 million against $781.4 million a year ago. Net income was $570.0 million against $753.5 million for the same period in the last year. Purchases of non-current investments were $4.9 million against $3.1 million for the same period in the last year. Purchases of PP&E were $39.8 million against $19.1 million for the same period in the last year. Non GAAP EBITDA was $1,368.8 million against $1,302.5 million for the same period in the last year. Non-GAAP operating income from continuing operations was $1,296.6 million against $1,221.0 million for the same period in the last year. Non GAAP cash generation was $1,021.1 million against $989.9 million a year ago. Net cash provided by operating activities was $1,013.9 million against $1,080.1 a year ago. Capital expenditure was $39.8 million against $19.1 million a year ago. For the quarter, impairment of IPR&D intangible assets were $523.3 million compared to $22.0 million a year ago. Non GAAP diluted earnings per ADS growth guidance increased to mid-to-high single digit % range for the full year 2015. The company expects to meet its 10x20 target of $6.5 billion of product sales in 2016, and exceed it with the contribution from its recent acquisition of NPS. For the year 2015, the company still expects its effective tax rate on non-GAAP income to be in the range of 15% to 17% before reverting to the 17% to 19% range in 2016 and beyond. The company expects non-GAAP net interest and other expense to remain in line with 2014 levels. Non-GAAP gross margin is still expected to be similar to 2014 levels.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SHPG:US $266.81 USD +4.29

SHPG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Biogen Inc $318.78 USD +1.78
CSL Ltd A$98.96 AUD +2.61
Eisai Co Ltd ¥8,095 JPY +11.00
Mylan NV $55.99 USD -0.36
Perrigo Co PLC $192.20 USD +0.77
View Industry Companies
 

Industry Analysis

SHPG

Industry Average

Valuation SHPG Industry Range
Price/Earnings 17.1x
Price/Sales 8.4x
Price/Book 5.7x
Price/Cash Flow 16.5x
TEV/Sales 8.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SHIRE PLC-ADR, please visit www.shire.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.